ID   TAOK3_HUMAN             Reviewed;         898 AA.
AC   Q9H2K8; Q658N1; Q8IUM4; Q9HC79; Q9NZM9; Q9UHG7;
DT   25-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 2.
DT   10-MAY-2017, entry version 143.
DE   RecName: Full=Serine/threonine-protein kinase TAO3;
DE            EC=2.7.11.1;
DE   AltName: Full=Cutaneous T-cell lymphoma-associated antigen HD-CL-09;
DE            Short=CTCL-associated antigen HD-CL-09;
DE   AltName: Full=Dendritic cell-derived protein kinase;
DE   AltName: Full=JNK/SAPK-inhibitory kinase;
DE   AltName: Full=Jun kinase-inhibitory kinase;
DE   AltName: Full=Kinase from chicken homolog A;
DE            Short=hKFC-A;
DE   AltName: Full=Thousand and one amino acid protein 3;
GN   Name=TAOK3; Synonyms=DPK, JIK, KDS, MAP3K18;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PHOSPHORYLATION, MUTAGENESIS OF THR-181
RP   AND TYR-183, AND FUNCTION.
RX   PubMed=10559204; DOI=10.1074/jbc.274.47.33287;
RA   Tassi E., Biesova Z., Di Fiore P.P., Gutkind J.S., Wong W.T.;
RT   "Human JIK, a novel member of the STE20 kinase family that inhibits
RT   JNK and is negatively regulated by epidermal growth factor.";
RL   J. Biol. Chem. 274:33287-33295(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Dendritic cell;
RX   PubMed=10924369; DOI=10.1006/bbrc.2000.3244;
RA   Zhang W., Chen T., Wan T., He L., Li N., Yuan Z., Cao X.;
RT   "Cloning of DPK, a novel dendritic cell-derived protein kinase
RT   activating the ERK1/ERK2 and JNK/SAPK pathways.";
RL   Biochem. Biophys. Res. Commun. 274:872-879(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], SELF-ASSOCIATION, TISSUE SPECIFICITY,
RP   VARIANT ASN-47, AND SUBCELLULAR LOCATION.
RX   PubMed=13679851; DOI=10.1038/sj.onc.1206605;
RA   Yustein J.T., Xia L., Kahlenburg J.M., Robinson D., Templeton D.,
RA   Kung H.-J.;
RT   "Comparative studies of a new subfamily of human Ste20-like kinases:
RT   homodimerization, subcellular localization, and selective activation
RT   of MKK3 and p38.";
RL   Oncogene 22:6129-6141(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASN-47.
RA   Carter T.G., Benton B., Fruhling D., Monks C.R.F., Windmiller D.,
RA   Kupfer A., Manfredi J., Johnson G.L., Pleiman C.M.;
RT   "KDS and TAO1, two related proteins with kinase domain homology to
RT   STE20, differentially relocate in mitogen stimulated T lymphocytes.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 191-898.
RC   TISSUE=Stomach;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 304-898.
RC   TISSUE=T-cell lymphoma;
RX   PubMed=14996095; DOI=10.1111/j.1365-2133.2004.05651.x;
RA   Hartmann T.B., Thiel D., Dummer R., Schadendorf D., Eichmueller S.;
RT   "SEREX identification of new tumour-associated antigens in cutaneous
RT   T-cell lymphoma.";
RL   Br. J. Dermatol. 150:252-258(2004).
RN   [10]
RP   INTERACTION WITH ERN1 AND TRAF2.
RX   PubMed=11278723; DOI=10.1074/jbc.M010677200;
RA   Yoneda T., Imaizumi K., Oono K., Yui D., Gomi F., Katayama T.,
RA   Tohyama M.;
RT   "Activation of caspase-12, an endoplastic reticulum (ER) resident
RT   caspase, through tumor necrosis factor receptor-associated factor 2-
RT   dependent mechanism in response to the ER stress.";
RL   J. Biol. Chem. 276:13935-13940(2001).
RN   [11]
RP   FUNCTION, PHOSPHORYLATION AT SER-324, INDUCTION, AND MUTAGENESIS OF
RP   ASP-165 AND SER-324.
RX   PubMed=17396146; DOI=10.1038/sj.emboj.7601668;
RA   Raman M., Earnest S., Zhang K., Zhao Y., Cobb M.H.;
RT   "TAO kinases mediate activation of p38 in response to DNA damage.";
RL   EMBO J. 26:2005-2014(2007).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-442, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-331, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   PHOSPHORYLATION BY LRRK2.
RX   PubMed=20949042; DOI=10.1371/journal.pone.0013191;
RA   Zach S., Felk S., Gillardon F.;
RT   "Signal transduction protein array analysis links LRRK2 to Ste20
RT   kinases and PKC zeta that modulate neuronal plasticity.";
RL   PLoS ONE 5:E13191-E13191(2010).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-324 AND SER-331, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-20; ASN-47; TYR-392 AND TYR-727.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a regulator
CC       of the p38/MAPK14 stress-activated MAPK cascade and of the
CC       MAPK8/JNK cascade. Acts as an activator of the p38/MAPK14 stress-
CC       activated MAPK cascade. In response to DNA damage, involved in the
CC       G2/M transition DNA damage checkpoint by activating the p38/MAPK14
CC       stress-activated MAPK cascade, probably by mediating
CC       phosphorylation of upstream MAP2K3 and MAP2K6 kinases. Inhibits
CC       basal activity of MAPK8/JNK cascade and diminishes its activation
CC       in response epidermal growth factor (EGF).
CC       {ECO:0000269|PubMed:10559204, ECO:0000269|PubMed:10924369,
CC       ECO:0000269|PubMed:17396146}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Self-associates. Interacts with ERN1 and TRAF2.
CC       Interaction with TRAF2 is facilitated under ER stress conditions,
CC       such as treatment with tunicamycin, and may promote TRAF2
CC       phosphorylation. {ECO:0000269|PubMed:11278723}.
CC   -!- INTERACTION:
CC       O75460:ERN1; NbExp=3; IntAct=EBI-1384100, EBI-371750;
CC       Q12933:TRAF2; NbExp=2; IntAct=EBI-1384100, EBI-355744;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:13679851}.
CC       Cell membrane {ECO:0000269|PubMed:13679851}; Peripheral membrane
CC       protein {ECO:0000269|PubMed:13679851}. Note=Also localized to the
CC       peripheral cell membrane.
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed at a low level, and
CC       highly expressed in peripheral blood leukocytes (PBLs), thymus,
CC       spleen, kidney, skeletal muscle, heart and liver.
CC       {ECO:0000269|PubMed:10924369, ECO:0000269|PubMed:13679851}.
CC   -!- PTM: Autophosphorylated. Phosphorylation at Ser-324 by ATM
CC       following DNA damage is required for activation of the p38/MAPK14
CC       stress-activated MAPK cascade. Phosphorylated by LRRK2.
CC       {ECO:0000269|PubMed:10559204, ECO:0000269|PubMed:17396146,
CC       ECO:0000269|PubMed:20949042}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAN09723.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF179867; AAF14559.1; -; mRNA.
DR   EMBL; AF135158; AAG09131.1; -; mRNA.
DR   EMBL; AF263311; AAG38501.1; -; mRNA.
DR   EMBL; AF181985; AAF25817.1; -; mRNA.
DR   EMBL; BT007185; AAP35849.1; -; mRNA.
DR   EMBL; AC026366; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC002756; AAH02756.1; -; mRNA.
DR   EMBL; AL833731; CAH56239.1; -; mRNA.
DR   EMBL; AF328731; AAN09723.1; ALT_INIT; mRNA.
DR   CCDS; CCDS9188.1; -.
DR   RefSeq; NP_001333417.1; NM_001346488.1.
DR   RefSeq; NP_001333418.1; NM_001346489.1.
DR   RefSeq; NP_057365.3; NM_016281.3.
DR   UniGene; Hs.644420; -.
DR   ProteinModelPortal; Q9H2K8; -.
DR   SMR; Q9H2K8; -.
DR   BioGrid; 119490; 8.
DR   IntAct; Q9H2K8; 6.
DR   MINT; MINT-5005619; -.
DR   STRING; 9606.ENSP00000376317; -.
DR   BindingDB; Q9H2K8; -.
DR   ChEMBL; CHEMBL5701; -.
DR   GuidetoPHARMACOLOGY; 2235; -.
DR   iPTMnet; Q9H2K8; -.
DR   PhosphoSitePlus; Q9H2K8; -.
DR   BioMuta; TAOK3; -.
DR   DMDM; 78099183; -.
DR   EPD; Q9H2K8; -.
DR   MaxQB; Q9H2K8; -.
DR   PaxDb; Q9H2K8; -.
DR   PeptideAtlas; Q9H2K8; -.
DR   PRIDE; Q9H2K8; -.
DR   DNASU; 51347; -.
DR   Ensembl; ENST00000392533; ENSP00000376317; ENSG00000135090.
DR   Ensembl; ENST00000419821; ENSP00000416374; ENSG00000135090.
DR   GeneID; 51347; -.
DR   KEGG; hsa:51347; -.
DR   UCSC; uc001twx.4; human.
DR   CTD; 51347; -.
DR   DisGeNET; 51347; -.
DR   GeneCards; TAOK3; -.
DR   HGNC; HGNC:18133; TAOK3.
DR   HPA; HPA017160; -.
DR   MIM; 616711; gene.
DR   neXtProt; NX_Q9H2K8; -.
DR   OpenTargets; ENSG00000135090; -.
DR   PharmGKB; PA134975064; -.
DR   eggNOG; KOG0577; Eukaryota.
DR   eggNOG; ENOG410Y259; LUCA.
DR   GeneTree; ENSGT00810000125351; -.
DR   HOGENOM; HOG000236358; -.
DR   HOVERGEN; HBG088996; -.
DR   InParanoid; Q9H2K8; -.
DR   KO; K04429; -.
DR   OMA; ENQIEYN; -.
DR   OrthoDB; EOG091G01CN; -.
DR   PhylomeDB; Q9H2K8; -.
DR   TreeFam; TF351444; -.
DR   SignaLink; Q9H2K8; -.
DR   SIGNOR; Q9H2K8; -.
DR   ChiTaRS; TAOK3; human.
DR   GeneWiki; TAOK3; -.
DR   GenomeRNAi; 51347; -.
DR   PRO; PR:Q9H2K8; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000135090; -.
DR   CleanEx; HS_TAOK3; -.
DR   ExpressionAtlas; Q9H2K8; baseline and differential.
DR   Genevisible; Q9H2K8; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004860; F:protein kinase inhibitor activity; TAS:ProtInc.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0016740; F:transferase activity; IDA:HGNC.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IDA:UniProtKB.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0000165; P:MAPK cascade; IMP:HGNC.
DR   GO; GO:0007095; P:mitotic G2 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IDA:HGNC.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IMP:HGNC.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IMP:UniProtKB.
DR   GO; GO:0032874; P:positive regulation of stress-activated MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:HGNC.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Cell membrane; Coiled coil;
KW   Complete proteome; Cytoplasm; DNA damage; DNA repair; Kinase;
KW   Membrane; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   CHAIN         1    898       Serine/threonine-protein kinase TAO3.
FT                                /FTId=PRO_0000086737.
FT   DOMAIN       24    277       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      30     38       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COILED      452    502       {ECO:0000255}.
FT   COILED      548    649       {ECO:0000255}.
FT   COILED      754    879       {ECO:0000255}.
FT   COMPBIAS    343    393       Ser-rich.
FT   ACT_SITE    147    147       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING      53     53       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     324    324       Phosphoserine; by ATM.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:17396146}.
FT   MOD_RES     331    331       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     343    343       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q53UA7}.
FT   MOD_RES     346    346       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BYC6}.
FT   MOD_RES     349    349       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BYC6}.
FT   MOD_RES     357    357       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8BYC6}.
FT   MOD_RES     359    359       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8BYC6}.
FT   MOD_RES     442    442       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     830    830       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8BYC6}.
FT   VARIANT      20     20       P -> T (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041205.
FT   VARIANT      47     47       S -> N (in dbSNP:rs428073).
FT                                {ECO:0000269|PubMed:13679851,
FT                                ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_023691.
FT   VARIANT     392    392       S -> Y (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041206.
FT   VARIANT     727    727       C -> Y (in dbSNP:rs55857273).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041207.
FT   MUTAGEN     165    165       D->A: Loss of serine/threonine-protein
FT                                kinase activity.
FT                                {ECO:0000269|PubMed:17396146}.
FT   MUTAGEN     181    181       T->A: No autophosphorylation and no
FT                                kinase activity; when associated with F-
FT                                183. {ECO:0000269|PubMed:10559204}.
FT   MUTAGEN     183    183       Y->F: No autophosphorylation and no
FT                                kinase activity; when associated with A-
FT                                181. {ECO:0000269|PubMed:10559204}.
FT   MUTAGEN     324    324       S->A: Inhibits activation of the
FT                                p38/MAPK14 stress-activated MAPK cascade
FT                                in response to DNA damage.
FT                                {ECO:0000269|PubMed:17396146}.
FT   CONFLICT    136    136       A -> T (in Ref. 3; AAG38501).
FT                                {ECO:0000305}.
FT   CONFLICT    173    173       S -> P (in Ref. 3; AAG38501).
FT                                {ECO:0000305}.
FT   CONFLICT    356    378       STGSQSSSVNSMQEVMDESSSEL -> TWNQPEQGNGQPGQ
FT                                QPFHSKHVR (in Ref. 1; AAF14559).
FT                                {ECO:0000305}.
FT   CONFLICT    668    668       Q -> R (in Ref. 3; AAG38501).
FT                                {ECO:0000305}.
SQ   SEQUENCE   898 AA;  105406 MW;  AE7E30745B09763C CRC64;
     MRKGVLKDPE IADLFYKDDP EELFIGLHEI GHGSFGAVYF ATNAHTSEVV AIKKMSYSGK
     QTHEKWQDIL KEVKFLRQLK HPNTIEYKGC YLKEHTAWLV MEYCLGSASD LLEVHKKPLQ
     EVEIAAITHG ALHGLAYLHS HALIHRDIKA GNILLTEPGQ VKLADFGSAS MASPANSFVG
     TPYWMAPEVI LAMDEGQYDG KVDIWSLGIT CIELAERKPP LFNMNAMSAL YHIAQNDSPT
     LQSNEWTDSF RRFVDYCLQK IPQERPTSAE LLRHDFVRRD RPLRVLIDLI QRTKDAVREL
     DNLQYRKMKK ILFQETRNGP LNESQEDEED SEHGTSLNRE MDSLGSNHSI PSMSVSTGSQ
     SSSVNSMQEV MDESSSELVM MHDDESTINS SSSVVHKKDH VFIRDEAGHG DPRPEPRPTQ
     SVQSQALHYR NRERFATIKS ASLVTRQIHE HEQENELREQ MSGYKRMRRQ HQKQLIALEN
     KLKAEMDEHR LKLQKEVETH ANNSSIELEK LAKKQVAIIE KEAKVAAADE KKFQQQILAQ
     QKKDLTTFLE SQKKQYKICK EKIKEEMNED HSTPKKEKQE RISKHKENLQ HTQAEEEAHL
     LTQQRLYYDK NCRFFKRKIM IKRHEVEQQN IREELNKKRT QKEMEHAMLI RHDESTRELE
     YRQLHTLQKL RMDLIRLQHQ TELENQLEYN KRRERELHRK HVMELRQQPK NLKAMEMQIK
     KQFQDTCKVQ TKQYKALKNH QLEVTPKNEH KTILKTLKDE QTRKLAILAE QYEQSINEMM
     ASQALRLDEA QEAECQALRL QLQQEMELLN AYQSKIKMQT EAQHERELQK LEQRVSLRRA
     HLEQKIEEEL AALQKERSER IKNLLERQER EIETFDMESL RMGFGNLVTL DFPKEDYR
//
